AmLactin® Alpha-Hydroxy Skin Care is proud to announce the introduction of AmLactin® Cerapeutic™ Restoring Body Lotion, formulated with skin care’s newest “power couple”— alpha-hydroxy acids (AHAs) and essential ceramides. Making its retail debut at select Wal-Mart and Walgreens stores, AmLactin® Cerapeutic™ contains the intensely hydrating, patented ULTRAPLEX® formula to gently exfoliate, and three skin identical ceramides that work together to quickly strengthen skin’s protective moisture barrier for noticeably softer, more resilient skin.
To view Multimedia News Release, go to http://www.multivu.com/mnr/60859-upsher-smith-amlactin-cerapeutic-restoring-body-lotion
Global gold demand in Q3 2012 was 1,084.6 tonnes (t), down 11% from the record Q3 2011 figure of 1,223.5t. This dip in demand is in comparison with exceptional demand in Q3 last year. Gold demand remains resilient. Q3 2012 was above the five year quarterly average of 984.7t, according to the World Gold Council’s Gold Demand Trends Report.
In value terms gold demand was 14.0% lower year on year at $57.6bn and the average gold price of $1,652/oz was down 3% on the record average Q3 2011 price.
To view Multimedia News Release, go to http://www.multivu.com/mnr/58938-world-gold-council-gold-demand-trends-report-q3-2012
Speaking at the annual TFWA World Exhibition Conference in Cannes on Monday 22nd October, Erik Juul-Mortensen, President of TFWA commented that, “Our brands, resilient and resourceful, demonstrated growth across all categories, with luxury goods leading the way.”
Attended by a record 894 delegates, it set the scene for TFWA World Exhibition which gave 462 brand-owners the opportunity to showcase thousands of products before buyers, agents, distributors and other trade visitors representing airports, airlines, airport retailers, ferry and cruise line companies and other duty free outlets. The exhibition occupied 21,000m2, the largest exhibition of its kind ever.
To view Multimedia News Release, go to http://www.multivu.com/mnr/58643-tfwa-world-exhibition-2012
C. R. Bard, Inc. today announced the publication of RESILIENT trial results by Circulation: Cardiovascular Interventions showing the Bard LifeStent® Vascular Stent improved patency and reduced revascularization rates in patients with moderate-length lesions in the superficial femoral artery (SFA) and proximal popliteal artery compared to patients treated with percutaneous transluminal angioplasty (PTA).
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/bard/44623/
